US regulators back multi-cancer blood test – but Hong Kong doctors remain cautious

AI Summary

US regulators have approved a multi-cancer detection blood test developed by the company Grail, marking a significant advancement in early cancer diagnosis. However, medical experts in Hong Kong remain cautious about its clinical validity and widespread adoption.

Efforts to detect multiple cancers through a single blood draw are gathering momentum after US regulators endorsed the technology for the first time, although experts say wider adoption in Hong Kong still faces challenges as doctors remain cautious about its clinical value. In a landmark decision for the emerging field of multi-cancer early detection (MCED) blood tests, a US Food and Drug Administration (FDA) panel on Thursday voted in favour of US company Grail’s “Galleri test”, recommending it...